Mechanism of Ursolic Acid-Mediated Inhibition of Proliferation in Vascular Endothelial Glioaytoma
Purpose: To investigate the effects of ursolic acid (UA) on expressions of ERK1, C-Jun, C-Myc and Cyclin D1 in Human Umbilical Vein Endothelial Cells (HUVEC), and to explore the mechanism of anticancer activity of UA on glioma.
Methods: HUVEC was treated with UA (0, 31.5, 62.5, 125, 250, 500 μg/mL) for 24 h, and 125 μg/mL for 0, 12, 24, 48 h, respectively) and PD98059 in vitro. Real-time polymerase chain reaction (RT-PCR) was performed to measure the endogenous mRNA levels of ERK1, C-Jun, C-Myc, and Cyclin D1, and Western blotting was used to determine the expressions of ERK1, C-Jun, C-Myc, and Cyclin D1 proteins.
Results: The results show that the mRNA levels of ERK1, C-Jun, C-Myc, and Cyclin D1 were downregulated, following treatment with UA (in a dose- and time-dependent manner) and PD98059 (p < 0.05). In addition, the protein expressions of ERK1, C-Jun, C-Myc, and cyclin D1 were all significantly down-regulated, after treatment with UA (in a dose- and time-dependent manner) and PD98059 (p < 0.05).
Conclusion: The findings indicate that UA can significantly inhibit the generation of vascular endothelial cells of glioma by down-regulating the expressions of ERK1, C-Jun, C-Myc and Cyclin D1 of ERK signal transduction pathway.
Keywords: Ursolic acid, Vascular endothelial cell, ERK signal pathway, Glioma, Down-regulation, Anticancer
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.